Funding profile · Life science tools
Kilobaser
No SEC filing exists for this company at any point in its history. What is on the record instead is an Austrian public register: about EUR 1.6 million invested by 2018, a US parent that lent its Austrian unit EUR 3.5 million, a 2023 insolvency, and a 2023 asset purchase financed by a distributor rather than a fund.
EUR 1.6MInvested by Apr 2018, as reported, mostly SOSV and FFG
EUR 5.2MLiabilities in the Jul 2023 insolvency of Kilobaser GmbH
EUR 3.5MOf those liabilities, a loan from the US parent, Kilobaser Corporation
$500KDevelopment orders from Biogenes Technologies financing the 2023/2024 buyout
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2014 | Founding, accelerator | $50,000, per PitchBook | BioTools Innovator accelerator | Aggregator |
| By Apr 2018 | Development funding to date | About EUR 1.6M | About EUR 500,000 from SOSV; remainder from FFG (Austria’s public research funder) | Independent |
| 2019 to 2021 | FFG Basisprogramm project | Amount not published | FFG | Public record |
| Around 2021 | Seed round reported | $125,000, per Nordic9 | Cathexis Ventures | Aggregator |
| Mar 2021 | Seed round sought | Target $2.0M | Not named; pitched during Y Combinator Winter 2021 | Company |
| Jul 2023 | Kilobaser GmbH insolvency | Liabilities about EUR 5.2M; assets about EUR 110,000 | About 30 creditors; EUR 3.5M of liabilities owed to Kilobaser Corporation (US parent) | Public record |
| Late 2023 to 2024 | Asset purchase out of bankruptcy | Development orders of about $500,000 | Biogenes Technologies (Malaysia), via new entity MABEAL GmbH | Independent |
| 2024 | MABEAL GmbH restructuring | Not disclosed | Restructuring proceeding without self administration; plan confirmed | Public record |
What the filings show
Kilobaser GmbH · Austrian Firmenbuch, FN 425447h · insolvency filed Jul 17, 2023
- Court
- Graz civil court (Landesgericht für Zivilrechtssachen Graz)
- Liabilities
- About EUR 5,195,000 to EUR 5.2M
- Assets
- About EUR 110,000, after write downs
- Creditors
- About 30, plus 19 employees
- Largest liability
- EUR 3.5M, a loan from Kilobaser Corporation, the US parent holding the share capital
- Outcome
- No continuation planned
- Filing
- Austrian insolvency register, via AKV and KSV1870
MABEAL GmbH · Austrian Firmenbuch, FN 609207v · registered Jul 28, 2023
- Share capital
- EUR 35,100
- Purpose
- Development and sale of biotechnological products and machines, trade in goods of all kinds
- Seat
- Graz
- Financing
- Buyout of Kilobaser assets backed by about $500,000 in development project orders from Biogenes Technologies, a Malaysian distributor and customer
- Later event
- Restructuring proceeding without self administration, announced Oct 20, 2024; plan legally confirmed, proceeding lifted, payment deadline to Sep 24, 2026
- Web presence
- Lists itself as responsible for kilobaser.com in the site’s imprint
- Filing
- Austrian business register, via wirtschaft.at
Reading the filings
- The 2023 insolvency was a US expansion failing to pay off, in the numbers.EUR 3.5 million of the EUR 5.2 million in liabilities was a loan from Kilobaser’s own US parent, Kilobaser Corporation. That is a related party balance, not outside debt, and it means most of the hole was money the corporate family had already put in and could not get back.
- No US securities filing exists for either side of the company.Neither “Kilobaser,” nor “Kilobaser Corporation,” nor the original name “Briefcase Biotec” turns up in an SEC EDGAR company or full text search. A company can raise money in the US without filing Form D if the offering is not a Regulation D offering, so the gap does not by itself mean no US money moved, but it does mean the size and structure of Kilobaser Corporation’s own capitalization is not independently documented.
- The buyer was a customer, by the founder’s own account.Alexander Murer described Biogenes Technologies as placing about $500,000 in development project orders, and said explicitly that it is “kein klassischer Investor,” not a conventional investor. That is a commercial relationship funding an asset purchase, distinct from an equity round, though it produced the same practical result: the Kilobaser product line continued under new ownership.
- The new company had its own financial event within about 15 months.MABEAL GmbH, registered in July 2023 with EUR 35,100 in capital, went through a restructuring proceeding without self administration announced in October 2024. The plan was legally confirmed and the proceeding lifted, with a payment deadline running to September 24, 2026, according to the Austrian business register. This is a second, separate distress event in the company’s short history, distinct from the 2023 Kilobaser GmbH insolvency.
- Aggregators disagree by more than 3 times on lifetime funding.Tracxn puts total funding at $625,000. PitchBook puts it at $1.99 million and marks the company “Out of Business,” a status that does not reflect MABEAL GmbH’s continued, Kilobaser branded operations. Neither figure matches the roughly EUR 1.6 million reported by Der Brutkasten for 2018 alone, converted at any plausible exchange rate.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Revenue estimate | About $3.1 million in 2024, a third party modeled estimate, not an audited figure. | Aggregator estimate |
| Headcount | About 14 employees as of 2026, per multiple aggregators; 18 of 20 pre insolvency staff retained through the 2023/2024 transition, per the founder. | Independent |
| Distribution | Named distributors include the Czech Republic and Malaysia (Biogenes Technologies, also the post insolvency financier). | Company stated |
| Product line | Kilobaser One and One-XT benchtop synthesizers in market; Kilobaser Industrial, a higher throughput version, and a nitrogen generator accessory (N2Go) announced for 2026. | Company stated |
| Intellectual property | US20190374946A1, granted patent on the synthesizer device, plus a pending microfluidic valve family (EP-3907006-A1, EP-4146396-A1, US-20230226547-A1, WO-2021224311-A1). | Public record |
What to watch
- Whether MABEAL GmbH meets the September 24, 2026 deadline under its restructuring plan.
- Any SEC filing, or its absence, for a US entity tied to the current business.
- Whether Biogenes Technologies is later described as an investor rather than a customer.
The Kilobaser story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordMABEAL GmbH, FN 609207v, register entry and insolvency database record
- Public recordFFG Projektdatenbank, project 3729535, Kilobaser
- IndependentGrazer Start-up Kilobaser ist insolvent
- IndependentKilobaser: 5-Millionen-Pleite für Grazer BioTech nach gescheiterter US-Expansion
- IndependentGrazer Medizin-Start-up Kilobaser GmbH ist insolvent
- IndependentNach Konkurs: Malaysischer Kunde finanziert Neugründung von Grazer Startup Kilobaser
- IndependentKilobaser: Grazer Startup geht mit “DNA-Nespresso-Maschine” an den Markt
- CompanyKilobaser joins Y-Combinator
- IndependentKilobaser raised more money (Cathexis Ventures, $125K)
- IndependentKilobaser 2026 Company Profile, Valuation, Funding & Investors
- IndependentKiloBaser, 2026 Company Profile, Team, Funding & Competitors
- IndependentKilobaser Revenue 2024, Est. ARR
- Public recordUS20190374946A1, Device for synthesizing oligonucleotides
Compiled from Austrian public registers, SEC EDGAR searches and published reports as of September 25, 2026. Austrian Firmenbuch entries reflect the register at the time of access; amounts labeled as reported come from independent news coverage and have not been independently verified against primary filings. Healthcare Venture Capital Fund holds no position in Kilobaser. This page is not an offer to sell or a recommendation to buy any security.